{
  "nctId": "NCT03000673",
  "briefTitle": "A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis",
  "officialTitle": "A Study to Assess Safety and Tolerability of Single Oral Doses of BMS-986177 in Patients With ESRD Treated With Chronic Hemodialysis",
  "protocolDocument": {
    "nctId": "NCT03000673",
    "filename": "Prot_002.pdf",
    "label": "Study Protocol",
    "date": "2017-09-06",
    "uploadDate": "2020-10-30T12:35",
    "size": 14715098,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03000673/document/Prot_002.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE1",
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "CROSSOVER",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 32,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-05-23",
    "completionDate": "2017-10-23",
    "primaryCompletionDate": "2017-10-23",
    "firstSubmitDate": "2016-12-20",
    "firstPostDate": "2016-12-22"
  },
  "eligibilityCriteria": {
    "criteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Subjects with ESRD treated with hemodialysis 3 times a week for at least 3 months prior enrollment.\n* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study treatment.\n* Women must not be breastfeeding\n* Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of treatment with study treatment(s) BMS-986177 plus 5 half-lives of study treatment (2 days) plus 30 days (duration of ovulatory cycle) for a total of 32 days post-treatment completion\n* Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study treatment(s) BMS-986177 plus 5 half-lives of the study treatment plus 90 days (duration of sperm turnover) for a total of 92 days post-treatment completion. In addition, male participants must be willing to refrain from sperm donation during this time.\n\nExclusion Criteria:\n\n* Subjects receiving dialysis through central venous catheters\n* History of uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, psychiatric and/or neurological disease in the past 3 months\n* Current or recent (within 3 months of study drug administration) gastrointestinal disease or surgery, which by the judgment of the Investigator, may increase a subject's risk of gastrointestinal bleeding or interfere with absorption of study drug (e.g., peptic or gastric ulcer disease, severe gastritis, history of gastrointestinal surgery).\n* Any major surgery within 12 weeks of study drug administration\n* History of significant head injury within the last 2 years, including subjects with base of skull fractures\n\nOther protocol defined inclusion/exclusion criteria could apply",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "75 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "The Number of Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Discontinuation and Death",
        "description": "Safety and tolerability of single oral doses of BMS-986177 in patients with end-stage renal disease (ESRD) on chronic hemodialysis (HD) treatment as measured by the number of participants with adverse events (AEs), serious AEs (SAEs), AEs leading to discontinuation and death",
        "timeFrame": "From the date of patient's written consent to participate in study until 30 days after discontinuation of dosing or patient's participation in study (up to October 2017)"
      },
      {
        "measure": "The Number of Participants Marked Abnormalities in Clinical Laboratory Tests : Hematology I; Hematology II; Coagulation",
        "description": "HEMATOLOGY I; HEMOGLOBIN HB G/DL LOW \\< 0.85\\*PRE-RX; HEMATOCRIT HCT % LOW \\< 0.85\\*PRE-RX; PLATELET COUNT PLAT X10\\*9 C/L LOW \\< 0.85\\*LLN IF PRE-RX IS MISSING; \\< 0.85\\*LLN IF PRE-RX \\>= LLN; \\< 0.85\\*PRE-RX IF PRE-RX \\< LLN; HIGH \\> 1.5\\*ULN; HEMATOLOGY II; LEUKOCYTES WBC X10\\*3 C/UL LOW \\< 0.9\\*LLN IF PRE-RX IS MISSING; \\< 0.9\\*LLN IF LLN \\<= PRE-RX \\<= ULN; \\< 0.85\\*PRE-RX IF PRE-RX \\< LLN; \\< LLN IF PRE-RX \\> ULN; HIGH \\> 1.2\\*ULN IF PRE-RX IS MISSING; \\> 1.2\\*ULN IF LLN \\<= PRE-RX \\<= ULN; \\> 1.5\\*PRE-RX IF PRE-RX \\> ULN; NEUTROPHILS (ABSOLUTE) NEUTA X10\\*3 C/UL LOW \\< 1.5 IF PRE-RX IS MISSING; \\< 1.5 IF PRE-RX \\>= 1.5; \\< 0.85\\*PRE-RX IF; PRE-RX \\< 1.5; LYMPHOCYTES (ABSOLUTE) LYMPA X10\\*3 C/UL LOW \\< 0.75; HIGH \\> 7.5; MONOCYTES (ABSOLUTE) MONOA X10\\*3 C/UL HIGH \\> 2; BASOPHILS (ABSOLUTE) BASOA X10\\*3 C/UL HIGH \\> 0.4; EOSINOPHILS (ABSOLUTE) EOSA X10\\*3 C/UL HIGH \\> 0.75; COAGULATION: PROTHROMBIN TIME (PT) PT SEC HIGH \\> 1.5\\*ULN; APTT APTT SEC HIGH \\> 1.5\\*ULN; INTL NORMALIZED RATIO (INR) INR FRACTION HIGH \\> 1.5\\*ULN;",
        "timeFrame": "At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge."
      },
      {
        "measure": "The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.) : Liver and Kidney Function",
        "description": "LIVER \\& KIDNEY FUNCTION; ALKALINE PHOSPHATASE (ALP) ALP U/L HIGH \\> 1.25\\*ULN IF PRE-RX IS MISSING; \\> 1.25\\*ULN IF PRE-RX \\<= ULN; \\> 1.25\\*PRE-RX IF PRE-RX \\> ULN; ASPARTATE AMINOTRANSFERASE (AST) AST U/L HIGH \\> 1.25\\*ULN IF PRE-RX IS MISSING; \\> 1.25\\*ULN IF PRE-RX \\<= ULN; \\> 1.25\\*PRE-RX IF PRE-RX \\> ULN; ALANINE AMINOTRANSFERASE (ALT) ALT U/L HIGH \\> 1.25\\*ULN IF PRE-RX IS MISSING; \\> 1.25\\*ULN IF PRE-RX \\<= ULN; \\> 1.25\\*PRE-RX IF PRE-RX \\> ULN; BILIRUBIN, TOTAL TBILI MG/DL HIGH \\> 1.1\\*ULN IF PRE-RX IS MISSING; \\> 1.1\\*ULN IF PRE-RX \\<= ULN; \\> 1.25\\*PRE-RX IF PRE-RX \\> ULN; BILIRUBIN, DIRECT DBILI MG/DL HIGH \\> 1.1\\*ULN IF PRE-RX IS MISSING; \\> 1.1\\*ULN IF PRE-RX \\<= ULN; \\> 1.25\\*PRE-RX IF PRE-RX \\> ULN; BLOOD UREA NITROGEN BUN MG/DL HIGH \\> 1.1\\*ULN IF PRE-RX IS MISSING; \\> 1.1\\*ULN IF PRE-RX \\<= ULN; \\> 1.2\\*PRE-RX IF PRE-RX \\> ULN; CREATININE CREAT MG/DL HIGH \\> 1.5\\*ULN IF PRE-RX IS MISSING; \\> 1.5\\*ULN IF PRE-RX \\<= ULN; \\> 1.33\\*PRE-RX IF PRE-RX \\> ULN;",
        "timeFrame": "At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge."
      },
      {
        "measure": "The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Electrolytes",
        "description": "ELECTROLYTES: SODIUM, SERUM NA MEQ/L LOW \\< 0.95\\*LLN IF PRE-RX IS MISSING; \\< 0.95\\*LLN IF PRE-RX \\>= LLN; \\< 0.95\\*PRE-RX IF PRE-RX \\< LLN; \\< LLN IF PRE-RX \\> ULN; HIGH \\> 1.05\\*ULN IF PRE-RX IS MISSING; \\> 1.05\\*ULN IF PRE-RX \\<= ULN; \\> 1.05\\*PRE-RX IF PRE-RX \\> ULN; \\> ULN IF PRE-RX \\< LLN; POTASSIUM, SERUM K MEQ/L LOW \\< 0.9\\*LLN IF PRE-RX IS MISSING; \\< 0.9\\*LLN IF PRE-RX \\>= LLN; \\< 0.9\\*PRE-RX IF PRE-RX \\< LLN; \\< LLN IF PRE-RX \\> ULN; HIGH \\> 1.1\\*ULN IF PRE-RX IS MISSING; \\> 1.1\\*ULN IF PRE-RX \\<= ULN; \\> 1.1\\*PRE-RX IF PRE-RX \\> ULN; \\> ULN IF PRE-RX \\< LLN; CHLORIDE, SERUM CL MEQ/L LOW \\< 0.9\\*LLN IF PRE-RX IS MISSING; \\< 0.9\\*LLN IF PRE-RX \\>= LLN; \\< 0.9\\*PRE-RX IF PRE-RX \\< LLN; \\< LLN IF PRE-RX \\> ULN; HIGH \\> 1.1\\*ULN IF PRE-RX IS MISSING; \\> 1.1\\*ULN IF PRE-RX \\<= ULN; \\> 1.1\\*PRE-RX IF PRE-RX \\> ULN; \\> ULN IF PRE-RX \\< LLN;",
        "timeFrame": "At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge"
      },
      {
        "measure": "The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Electrolytes (Cont.)",
        "description": "ELECTROLYTES (CONT.): CALCIUM, TOTAL CA MG/DL LOW \\< 0.9\\*LLN IF PRE-RX IS MISSING; \\< 0.9\\*LLN IF PRE-RX \\>= LLN; \\< 0.9\\*PRE-RX IF PRE-RX \\< LLN; \\< LLN IF PRE-RX \\> ULN; HIGH \\> 1.1\\*ULN IF PRE-RX IS MISSING; \\> 1.1\\*ULN IF PRE-RX \\<= ULN; \\> 1.1\\*PRE-RX IF PRE-RX \\> ULN; \\> ULN IF PRE-RX \\< LLN; PHOSPHORUS, INORGANIC PHOS MG/DL LOW \\< 0.85\\*LLN IF PRE-RX IS MISSING; \\< 0.85\\*LLN IF PRE-RX \\>= LLN; \\< 0.85\\*PRE-RX IF PRE-RX \\< LLN; \\< LLN IF PRE-RX \\> ULN; HIGH \\> 1.25\\*ULN IF PRE-RX IS MISSING; \\> 1.25\\*ULN IF PRE-RX \\<= ULN; \\> 1.25\\*PRE-RX IF PRE-RX \\> ULN; \\> ULN IF PRE-RX \\< LLN; MAGNESIUM, SERUM MG MEQ/L LOW \\< 0.9\\*LLN IF PRE-RX IS MISSING; \\< 0.9\\*LLN IF PRE-RX \\>= LLN; \\< 0.9\\*PRE-RX IF PRE-RX \\< LLN; \\< LLN IF PRE-RX \\> ULN; HIGH \\> 1.1\\*ULN IF PRE-RX IS MISSING; \\> 1.1\\*ULN IF PRE-RX \\<= ULN; \\> 1.1\\*PRE-RX IF PRE-RX \\> ULN; \\> ULN IF PRE-RX \\< LLN",
        "timeFrame": "At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge."
      },
      {
        "measure": "The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Other Chemistry Testing",
        "description": "GLUCOSE, FASTING SERUM GLUCF MG/DL LOW \\< 0.8\\*LLN IF PRE-RX IS MISSING; \\< 0.8\\*LLN IF PRE-RX \\>= LLN; \\< 0.8\\*PRE-RX IF PRE-RX \\< LLN; \\< LLN IF PRE-RX \\> ULN; HIGH \\> 1.3\\*ULN IF PRE-RX IS MISSING \\> 1.3\\*ULN IF PRE-RX \\<= ULN; \\> 2\\*PRE-RX IF PRE-RX \\> ULN; \\> ULN IF PRE-RX \\< LLN; PROTEIN, TOTAL TPRO G/DL LOW \\< 0.9\\*LLN IF PRE-RX IS MISSING; \\< 0.9\\*LLN IF PRE-RX \\>= LLN; \\< 0.9\\*PRE-RX IF PRE-RX \\< LLN; \\< LLN IF PRE-RX \\> ULN HIGH \\> 1.1\\*ULN IF PRE-RX IS MISSING; \\> 1.1\\*ULN IF PRE-RX \\<= ULN; \\> 1.1\\*PRE-RX IF PRE-RX \\> ULN; \\> ULN IF PRE-RX \\< LLN; ALBUMIN ALB G/DL LOW \\< 0.9\\*LLN IF PRE-RX IS MISSING; \\< 0.9\\*LLN IF PRE-RX \\>= LLN; \\< 0.9\\*PRE-RX IF PRE-RX \\< LLN; CREATINE KINASE (CK) CK U/L HIGH \\> 1.5\\*ULN IF PRE-RX IS MISSING; \\> 1.5\\*ULN IF PRE-RX \\<= ULN; \\> 1.5\\*PRE-RX IF PRE-RX \\> ULN; URIC ACID URIC MG/DL HIGH \\> 1.2\\*ULN IF PRE-RX IS MISSING; \\> 1.2\\*ULN IF PRE-RX \\<= ULN; \\> 1.25\\*PRE-RX IF PRE-RX \\> ULN; LACTATE DEHYDR (LD) LD U/L HIGH \\> 1.25\\*ULN IF PRE-RX IS MISSING; \\> 1.25\\*ULN IF PRE-RX \\<= ULN; \\> 1.5\\*PRE-RX IF PRE-RX \\> ULN",
        "timeFrame": "At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge."
      },
      {
        "measure": "The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.) : Urinalysis I, Special Studies",
        "description": "URINALYSIS I; BLOOD, URINE UBLD N/A HIGH \\>= 2 IF PRE-RX IS MISSING; \\>= 2 IF PRE-RX \\< 1; \\>= 2 IF PRE-RX \\>= 1 SPECIAL STUDIES; OCCULT BLOOD SCREEN, FECES OCBLD N/A HIGH NEGATIVE PRE-RX CHANGING TO POSITIVE",
        "timeFrame": "At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge."
      },
      {
        "measure": "The Change From Baseline in Electrocardiogram (ECG) Parameters: Mean Heart Rate",
        "description": "Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.",
        "timeFrame": "Days -3 to -1, Days 1, 5, 8, and 12."
      },
      {
        "measure": "The Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, Aggregate",
        "description": "Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.",
        "timeFrame": "Days -3 to -1, Days 1, 5, 8, and 12."
      },
      {
        "measure": "The Change From Baseline in Electrocardiogram (ECG) Parameters: QRS Duration, Aggregate",
        "description": "Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.",
        "timeFrame": "Days -3 to -1, Days 1, 5, 8, and 12."
      },
      {
        "measure": "The Change From Baseline in Electrocardiogram (ECG) Parameters: QT Interval, Aggregate",
        "description": "Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.",
        "timeFrame": "Days -3 to -1, Days 1, 5, 8, and 12."
      },
      {
        "measure": "The Change From Baseline in Electrocardiogram (ECG) Parameters: QTcF Interval, Aggregate",
        "description": "QTcF = QT corrected for heart rate using the Fridericia formula Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.",
        "timeFrame": "Days -3 to -1, Days 1, 5, 8, and 12"
      },
      {
        "measure": "The Change From Baseline in Vital Signs: Diastolic Blood Pressure",
        "timeFrame": "Days -3 to -1, 1, 5, 8, 12 and at study discharge on day 13 to day 15"
      },
      {
        "measure": "The Change From Baseline in Vital Signs: Systolic Blood Pressure (mm Hg)",
        "timeFrame": "Days -3 to -1, 1, 5, 8, 12 and at study discharge on day 13 to day 15"
      },
      {
        "measure": "The Change From Baseline in Vital Signs: Heart Rate (Beats/Min)",
        "timeFrame": "Days -3 to -1, 1, 5, 8, 12 and at study discharge on day 13 to day 15"
      }
    ],
    "secondary": [
      {
        "measure": "Pharmacokinetic Parameters of BMS-986177: Cmax",
        "description": "Cmax: Maximum observed plasma concentration",
        "timeFrame": "Either Day 1, 5, 8, or 12 depending on the randomization sequence"
      },
      {
        "measure": "Pharmacokinetic Parameters of BMS-986177: Tmax",
        "description": "Time of maximum observed plasma concentration",
        "timeFrame": "Either Day 1, 5, 8, or 12 depending on the randomization sequence"
      },
      {
        "measure": "Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (0-T), AUC (0-24)",
        "description": "AUC(0-T) Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration AUC(0-24) Area under the plasma concentration-time curve from time zero to 24 hours",
        "timeFrame": "Either Day 1, 5, 8, or 12 depending on the randomization sequence"
      },
      {
        "measure": "Pharmacokinetic Parameters of BMS-986177: fu",
        "description": "Fraction of unbound drug",
        "timeFrame": "Either Day 1, 5, 8, or 12 depending on the randomization sequence"
      },
      {
        "measure": "Pharmacokinetic Parameters of BMS-986177: Cmaxfu",
        "description": "Maximum observed plasma concentration of free drug",
        "timeFrame": "Either Day 1, 5, 8, or 12 depending on the randomization sequence"
      },
      {
        "measure": "Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (0-T)fu",
        "description": "AUC(0-T)fu Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration of free drug",
        "timeFrame": "Either Day 1, 5, 8, or 12 depending on the randomization sequence"
      },
      {
        "measure": "Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (3-7)",
        "description": "AUC (3-7) : Area under the plasma concentration-time curve from 3 to 7 hours (ie, during dialysis.\n\nDetermined from blood samples entering and exiting the dialyzer)",
        "timeFrame": "Either Day 1, 5, 8, or 12 depending on the randomization sequence"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 15,
      "secondaryCount": 7,
      "otherCount": 0,
      "totalCount": 22
    },
    "studyDesign": {
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "CROSSOVER"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:07.197Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}